Jin Yunfeng, Lin Qiwang, Fei He, Xue Lujie, Li Li, Xi Qinghua, Jiang Hua
Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China.
J Oncol. 2021 Jan 28;2021:8859554. doi: 10.1155/2021/8859554. eCollection 2021.
Ovarian cancer (OC) is one of the leading lethal gynecologic cancers of women around the world. More than 70% of patients are diagnosed with stage III or IV with poor outcome. This is partly because of lacking early effective screening techniques and potential biomarkers of OC. CXC chemokines in tumor microenvironment (TME) and their interaction with relative receptors can excite the downstream signaling pathways to influence tumor progression. However, the role of CXC chemokines in OC has not been identified.
ONCOMINE, GEPIA, Kaplan-Meier plotter, cBioPortal, TIMER, Metascape, and LinkedOmics were applied in our study.
The transcriptional levels of CXCL1/8/9/10/11/12/13/14/16/17 were significantly elevated while CXCL3 was obviously reduced in OC vs normal ovarian tissue. CXCL8/9/11/13 were correlated with clinic pathological stage. Patients with low expression of CXCL8/9/11/13 were associated with better prognosis. We also found that CXCL3 and CXC12 could be used as potential prognostic markers of OC through Kaplan-Meier plotter. Patients with high expression of CXCL3/12 had a significantly better prognosis. Their functions focus on locomotion, signaling, response to stimulus, undergoing the process of multiorganism, immune system, biological regulation, etc. The differentiated CXC chemokines mainly participate in cytokine-cytokine receptor interaction, chemokine signaling pathway, IL-17 signaling pathway, and toll-like receptor signaling pathway. Our results showed that CXC chemokines were highly correlated with infiltration of immune cells. The kinase targets of differentially expressed CXC chemokines are mainly in ATM, LYN, LCK, PLK1, FYN, CDK2, and ATR.
Our results may provide a new insight for selecting precision biomarkers of targeted therapy of OC.
卵巢癌(OC)是全球女性主要的致死性妇科癌症之一。超过70%的患者被诊断为III期或IV期,预后较差。部分原因是缺乏早期有效的筛查技术和卵巢癌的潜在生物标志物。肿瘤微环境(TME)中的CXC趋化因子及其与相关受体的相互作用可激活下游信号通路,影响肿瘤进展。然而,CXC趋化因子在卵巢癌中的作用尚未明确。
本研究应用了ONCOMINE、GEPIA、Kaplan-Meier plotter、cBioPortal、TIMER、Metascape和LinkedOmics。
与正常卵巢组织相比,OC中CXCL1/8/9/10/11/12/13/14/16/17的转录水平显著升高,而CXCL3明显降低。CXCL8/9/11/13与临床病理分期相关。CXCL8/9/11/13低表达的患者预后较好。通过Kaplan-Meier plotter分析,我们还发现CXCL3和CXC12可作为OC的潜在预后标志物。CXCL3/12高表达的患者预后明显较好。它们的功能集中在运动、信号传导、对刺激的反应、经历多生物体过程、免疫系统、生物调节等方面。分化的CXC趋化因子主要参与细胞因子-细胞因子受体相互作用、趋化因子信号通路、IL-17信号通路和Toll样受体信号通路。我们的结果表明,CXC趋化因子与免疫细胞浸润高度相关。差异表达的CXC趋化因子的激酶靶点主要在ATM、LYN、LCK、PLK1、FYN、CDK2和ATR中。
我们的结果可能为选择卵巢癌靶向治疗的精准生物标志物提供新的见解。